Kestra Medical Technologies (NASDAQ:KMTS) Shares Gap Down – What’s Next?

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) gapped down before the market opened on Thursday . The stock had previously closed at $21.82, but opened at $20.45. Kestra Medical Technologies shares last traded at $20.72, with a volume of 869 shares traded.

Analyst Ratings Changes

A number of equities analysts recently issued reports on KMTS shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kestra Medical Technologies in a research report on Monday, March 23rd. BTIG Research reiterated a “buy” rating and set a $32.00 price target on shares of Kestra Medical Technologies in a report on Tuesday, April 7th. Finally, The Goldman Sachs Group cut their price target on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $27.40.

Kestra Medical Technologies Trading Up 0.6%

The company has a market cap of $1.23 billion, a price-to-earnings ratio of -5.31 and a beta of 0.82. The business’s fifty day moving average price is $20.65 and its 200 day moving average price is $23.58. The company has a debt-to-equity ratio of 0.15, a current ratio of 7.32 and a quick ratio of 7.32.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings results on Tuesday, March 17th. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). The business had revenue of $24.55 million for the quarter. Kestra Medical Technologies had a negative return on equity of 65.49% and a negative net margin of 171.87%.The company’s revenue for the quarter was up 62.7% on a year-over-year basis. Research analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.34 earnings per share for the current fiscal year.

Insider Buying and Selling at Kestra Medical Technologies

In other news, insider Brian Daniel Webster sold 15,000 shares of the stock in a transaction on Friday, May 15th. The shares were sold at an average price of $20.96, for a total transaction of $314,400.00. Following the completion of the sale, the insider directly owned 334,786 shares in the company, valued at $7,017,114.56. This represents a 4.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold 45,000 shares of company stock worth $919,050 in the last ninety days. Corporate insiders own 3.60% of the company’s stock.

Institutional Investors Weigh In On Kestra Medical Technologies

Several large investors have recently modified their holdings of KMTS. Price T Rowe Associates Inc. MD increased its position in shares of Kestra Medical Technologies by 137.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock worth $115,878,000 after buying an additional 2,529,851 shares during the period. Franklin Resources Inc. increased its position in shares of Kestra Medical Technologies by 180.8% during the fourth quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock worth $25,221,000 after buying an additional 612,343 shares during the period. Millennium Management LLC acquired a new stake in shares of Kestra Medical Technologies during the first quarter worth $11,036,000. Brown Advisory Inc. increased its position in shares of Kestra Medical Technologies by 34.1% during the fourth quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock worth $44,775,000 after buying an additional 428,996 shares during the period. Finally, Summit Partners Public Asset Management LLC acquired a new stake in shares of Kestra Medical Technologies during the fourth quarter worth $9,282,000.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.